NCT03420053 - Study to Evaluate Safety, Immunogenicity and Efficacy of PfSPZ Vaccine in HIV Negative and HIV Positive Tanzanian Adults | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 7, 2018

Primary Completion Date

August 25, 2018

Study Completion Date

August 25, 2018

Conditions

MalariaMalaria,Falciparum

Interventions

BIOLOGICAL

PfSPZ Vaccine

Aseptic, purified, metabolically active, non-replicating, radiation-attenuated, cryopreserved Pf sporozoites.

OTHER

Normal Saline Placebo

0.9% sodium chloride solution

BIOLOGICAL

PfSPZ Challenge

Aseptic, purified, live, infectious, cryopreserved Pf sporozoites.

Trial Locations (1)

Bagamoyo Research and Training Center of the Ifakara Health Institute, Bagamoyo